Hikal (HIKAL)
TurnaroundFairStock Score: 29/100 — RISKY
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹217.99 |
| Market Cap | ₹2,687.83 Cr |
| P/E Ratio | 97 |
| ROCE | 9.85% |
| ROE | -1.08% |
| Dividend Yield | 0.46% |
| Profit Growth | 68.3% |
| Debt/Equity | — |
| Sales Growth | 37.3% |
| Promoter Holding | 68.85% |
| 52-Week Range | ₹146.25 — ₹261 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹97.4 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At ₹187, Hikal asks me to pay ₹2,425 Cr for a business whose latest quarter lost ₹6 Cr on sales of ₹494 Cr. That immediately fails my first test: a decent return on equity. ROE is -1.08%; the company is destroying book value, not compounding it. Book value is ₹98.44, so the market price of ₹187 is 1.9 times tangible book for a subpar earner. Graham would call that speculation, not investment.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer